Colistin Purification via Reverse Phase Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current colistin products contain a mixture of active and inactive substances, leading to unknown toxicological and pharmacological properties, making standardization of dosing and analysis challenging, and limiting their effectiveness and safety in treating multidrug-resistant infections.
Innovation Solution
A method for producing a virtually pure preparation of polymyxin E1 (90-98% purity) using reverse phase chromatography followed by hydrophobic interaction chromatography, which efficiently separates polymyxin E1 from other colistin components, resulting in a mono-component colistin product with improved purity and defined derivatives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional fermentation and purification methods are used to produce colistin, then production cost and process simplicity are maintained, but the product contains a mixture of active and inactive substances with unknown toxicological properties
Solution Approach 1:
The patent applies segmentation by dividing the complex colistin mixture into individual separable components through chromatographic techniques. Reverse phase chromatography separates polymyxin E1 from other colistin components (E2, E3, E4), and hydrophobic interaction chromatography further purifies the fractions. This segmentation enables individual characterization of each component's toxicological and pharmacological properties, resolving the reliability issue while managing complexity through systematic separation.
Solution Approach 2:
The patent extracts the main active component polymyxin E1 from the complex colistin mixture produced by fermentation. By using reverse phase chromatography with specific mobile phases (acetonitrile/water or methanol/water gradients) and hydrophobic interaction chromatography, the invention isolates polymyxin E1 as a purified product, removing inactive and potentially toxic impurities. This extraction approach maintains production feasibility while enabling reliable toxicological assessment of the isolated component.
2Manufacturing precision
If colistin is used as a mixture of components, then manufacturing is simpler, but dosing standardization and pharmacological assessment become challenging
Solution Approach 1:
The patent applies preliminary action by performing comprehensive purification and separation of colistin components before final product formulation. Reverse phase chromatography is used first to separate polymyxin E1 from other components, followed by hydrophobic interaction chromatography for further purification. This preliminary separation establishes a well-defined, standardized product with known composition and potency, enabling precise dosing recommendations and pharmacological assessment while the purification processes are optimized for manufacturing scalability.
Solution Approach 2:
The patent utilizes parameter changes in chromatographic conditions to achieve separation and purification. Reverse phase chromatography employs gradient elution with changing organic solvent concentrations (acetonitrile or methanol percentages), while hydrophobic interaction chromatography uses salt concentration gradients. These controlled parameter changes enable selective separation of colistin components, producing a standardized polymyxin E1 product with defined potency for accurate dosing.
3Object-affected harmful factors
If colistimethate sodium is used as a pro-drug, then toxicity is reduced, but the product becomes less potent and requires complex hydrolysis analysis
Solution Approach 1:
The patent uses chromatographic purification as an intermediary process to obtain highly pure polymyxin E1, which can then be used to synthesize colistimethate sodium pro-drug with well-defined starting material. The purification process (reverse phase followed by hydrophobic interaction chromatography) acts as an intermediary step that ensures the pro-drug synthesis begins with a single, characterized component rather than a mixture, enabling controlled synthesis and accurate potency determination while maintaining the desired toxicity-reduced properties of the pro-drug formulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high purity and recovery of polymyxin E1, enabling clearer toxicological and pharmacological assessments, facilitating precise dosing recommendations, and simplifying regulatory procedures, thereby upgrading colistin to a more modern and effective antibiotic.
Implementation Method 1
reverse phase chromatography, which allow purification of Polymyxin E1 to a purity of more than 90%
Implementation Method 2
followed by hydrophobic interaction chromatography
Data Source
AI summary
The present invention concerns a method of purifying colistin using reverse phase chromatography, wherein loading a column with colistin base in acetic acid and high ethanol concentration and eluting with low ethanol concentration is performed.